HLN trades 12.0% below Wall Street's consensus target of $10.20.
Last 12 months price action with 12-month analyst target path
The base valuation assumes HLN achieves its forward estimates and maintains a stable P/E multiple of 21.4x. This scenario reflects the blended consensus of 4 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
As of September 24, 2026, Haleon plc (HLN) has a Wall Street consensus price target of $10.20, based on estimates from 4 covering analysts. With the stock currently trading at $9.11, this represents a potential upside of +12.0%. The company has a market capitalization of $40.63B.
Analyst price targets range from a low of $10.20 to a high of $10.20, representing a 0% spread in expectations. The median target of $10.20 aligns closely with the consensus average. The tight target dispersion indicates high conviction among analysts.
The current analyst consensus rating is Buy, with 3 analysts rating the stock as a Buy or Strong Buy,1 rating it Hold, and 0 rating it Sell or Strong Sell. This overwhelmingly bullish sentiment suggests analysts see significant catalysts for upside ahead.
From a valuation perspective, HLN trades at a trailing P/E of 19.1x and forward P/E of 21.4x. The forward PEG ratio of 2.54 reflects a premium valuation. Analysts expect EPS to grow -39.7% over the next year.
Our proprietary valuation model, which blends historical multiples with forward estimates, suggests a base-case price target of $12.37, with bear and bull scenarios of $7.80 and $16.30 respectively. Model confidence stands at 37/100, suggesting limited visibility into future performance.
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
 KVUEKenvue Inc. | $33.9B | $17.67 | $19.50 | +10.4% | Hold | 15.0x | 14 |
 CHDChurch & Dwight Co., Inc. | $22.8B | $96.03 | $108.88 | +13.4% | Buy | 25.4x | 34 |
 PGThe Procter & Gamble Company | $343.4B | $147.45 | $157.78 | +7.0% | Buy | 21.1x | 53 |
 CLColgate-Palmolive Company | $68.8B | $85.93 | $97.78 | +13.8% | Hold | 22.2x | 45 |
 PBHPrestige Consumer Healthcare Inc. | $2.2B | $45.92 | $81.67 | +77.9% | Buy | 10.0x | 17 |
 JNJJohnson & Johnson | $648.0B | $269.17 | $286.93 | +6.6% | Buy | 23.4x | 40 |
 NVSNovartis AG | $271.3B | $142.71 | $153.00 | +7.2% | Hold | 16.2x | 25 |
 GSKGSK plc | $99.6B | $49.71 | $60.00 | +20.7% | Hold | 13.8x | 29 |
 MCKMcKesson Corporation | $105.0B | $880.50 | $953.00 | +8.2% | Buy | 19.7x | 31 |
 CAHCardinal Health, Inc. | $51.8B | $221.27 | $273.22 | +23.5% | Buy | 17.6x | 33 |
Quick answers to the most common questions about buying HLN stock.
Haleon plc (HLN) has a consensus 12-month price target of $10.2, implying 12.0% upside from $9.11. The 4 analysts covering HLN see moderate appreciation potential.
HLN has a consensus rating of "Buy" based on 4 Wall Street analysts. The rating breakdown is predominantly bullish, with 3 Buy/Strong Buy ratings. The consensus 12-month price target of $10.2 implies 12.0% upside from current levels.
HLN trades at a forward P/E of 21.4303x, representing a moderate valuation. With analysts targeting $10.2 (12.0% implied move), the stock appears reasonably valued with upside.
The most bullish Wall Street analyst has a price target of $10.2 for HLN, while the most conservative target is $10.2. The consensus of $10.2 represents the median expectation. Our quantitative valuation model projects a bull case target of $16 based on optimistic growth and margin assumptions. These targets typically reflect 12-month expectations.
HLN is lightly followed, with 4 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 3 have Buy ratings, 1 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month HLN stock forecast based on 4 Wall Street analysts shows a consensus price target of $10.2, with estimates ranging from $10.2 (bear case) to $10.2 (bull case). The median consensus rating is "Buy". Our proprietary valuation model produces a base case fair value of $12, with bear/bull scenarios of $8/$16.
Our quantitative valuation model calculates HLN's fair value at $12 (base case), with a bear case of $8 and bull case of $16. The model uses discounted cash flow analysis, historical growth rates, and margin mean-reversion to project FY+2 earnings, then applies an appropriate P/E multiple. The model confidence score is 37/100.
HLN trades at a forward P/E ratio of 21.4x based on next-twelve-months earnings estimates compared to a trailing P/E of 19.1x. The higher forward P/E suggests near-term earnings pressure. A forward P/E is useful for comparing valuations when earnings are expected to change significantly.
Wall Street analysts are optimistic on HLN, with a "Buy" consensus rating and $10.2 price target (12.0% upside). 3 of 4 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
HLN analyst price targets range from $10.2 to $10.2, a 0% tight range reflecting strong analyst consensus. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $10.2 consensus represents the middle ground. Our model's $8-$16 range provides an independent fundamental perspective.
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.